Impact of allulose on blood glucose in type 2 diabetes: A meta-analysis of clinical trials

Metabolism open Pub Date : 2024-11-07 DOI:10.1016/j.metop.2024.100329

Hazem Ayesh , Sajida Suhail , Suhail Ayesh

{"title":"Impact of allulose on blood glucose in type 2 diabetes: A meta-analysis of clinical trials","authors":"Hazem Ayesh , Sajida Suhail , Suhail Ayesh","doi":"10.1016/j.metop.2024.100329","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This meta-analysis aims to evaluate the impact of allulose on blood glucose levels in patients with type 2 diabetes mellitus (T2DM). Primary outcomes include postprandial blood glucose, while secondary outcomes are time in range (TIR), time above range (TAR), fasting plasma glucose (FPG), and insulin area under the curve (AUC).</div></div><div><h3>Methods</h3><div>A systematic search was conducted across PubMed/MEDLINE, Web of Science, Scopus, and Cochrane Library until May 20, 2024. Randomized controlled trials assessing the effect of allulose on glycemic parameters in T2DM patients were included. Data were synthesized using a random-effects meta-analysis model, and the quality of studies was assessed using the Cochrane Risk of Bias tool.</div></div><div><h3>Results</h3><div>Six studies involving 126 participants were included. Allulose significantly reduced glucose AUC (SMD: −0.6662, 95 % CI [-1.1360, −0.1964], p = 0.0054) with moderate heterogeneity (I<sup>2</sup> = 58.3 %). Insulin AUC showed a non-significant reduction (SMD: −0.3648, 95 % CI [-0.7783, 0.0488], p = 0.0839). FPG demonstrated a non-significant reduction (MD: −5.8925, 95 % CI [-20.4892, 8.7043], p = 0.4288), while TAR significantly decreased (MD: −8.8204, 95 % CI [-14.4101, −3.2307], p = 0.0020). No significant changes were observed in TIR (MD: 7.1211, 95 % CI [-1.6028, 15.8450], p = 0.1096).</div></div><div><h3>Conclusion</h3><div>Allulose demonstrated a significant reduction in postprandial glucose levels and TAR, supporting its role as a dietary intervention for glycemic control in T2DM patients. The findings are robust, though further research is needed to confirm its long-term effects on insulin sensitivity and metabolic health.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"24 ","pages":"Article 100329"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolism open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589936824000616","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This meta-analysis aims to evaluate the impact of allulose on blood glucose levels in patients with type 2 diabetes mellitus (T2DM). Primary outcomes include postprandial blood glucose, while secondary outcomes are time in range (TIR), time above range (TAR), fasting plasma glucose (FPG), and insulin area under the curve (AUC).

Methods

A systematic search was conducted across PubMed/MEDLINE, Web of Science, Scopus, and Cochrane Library until May 20, 2024. Randomized controlled trials assessing the effect of allulose on glycemic parameters in T2DM patients were included. Data were synthesized using a random-effects meta-analysis model, and the quality of studies was assessed using the Cochrane Risk of Bias tool.

Results

Six studies involving 126 participants were included. Allulose significantly reduced glucose AUC (SMD: −0.6662, 95 % CI [-1.1360, −0.1964], p = 0.0054) with moderate heterogeneity (I² = 58.3 %). Insulin AUC showed a non-significant reduction (SMD: −0.3648, 95 % CI [-0.7783, 0.0488], p = 0.0839). FPG demonstrated a non-significant reduction (MD: −5.8925, 95 % CI [-20.4892, 8.7043], p = 0.4288), while TAR significantly decreased (MD: −8.8204, 95 % CI [-14.4101, −3.2307], p = 0.0020). No significant changes were observed in TIR (MD: 7.1211, 95 % CI [-1.6028, 15.8450], p = 0.1096).

Conclusion

Allulose demonstrated a significant reduction in postprandial glucose levels and TAR, supporting its role as a dietary intervention for glycemic control in T2DM patients. The findings are robust, though further research is needed to confirm its long-term effects on insulin sensitivity and metabolic health.

查看原文本刊更多论文

阿洛糖对 2 型糖尿病患者血糖的影响：临床试验荟萃分析

本荟萃分析旨在评估阿洛糖对 2 型糖尿病 (T2DM) 患者血糖水平的影响。主要结果包括餐后血糖，次要结果包括在量程内的时间（TIR）、超过量程的时间（TAR）、空腹血浆葡萄糖（FPG）和胰岛素曲线下面积（AUC）。方法截至 2024 年 5 月 20 日，在 PubMed/MEDLINE、Web of Science、Scopus 和 Cochrane Library 上进行了系统检索。纳入了评估阿洛糖对 T2DM 患者血糖参数影响的随机对照试验。采用随机效应荟萃分析模型对数据进行了综合分析，并使用 Cochrane 偏倚风险工具对研究质量进行了评估。阿洛糖能明显降低血糖 AUC（SMD：-0.6662，95 % CI [-1.1360，-0.1964]，p = 0.0054），异质性适中（I2 = 58.3 %）。胰岛素 AUC 下降不显著（SMD：-0.3648，95 % CI [-0.7783，0.0488]，p = 0.0839）。FPG 下降不明显（MD：-5.8925，95 % CI [-20.4892，8.7043]，p = 0.4288），而 TAR 显著下降（MD：-8.8204，95 % CI [-14.4101，-3.2307]，p = 0.0020）。结论阿洛糖能显著降低餐后血糖水平和 TAR，支持其作为 T2DM 患者血糖控制的饮食干预措施。研究结果是可靠的，但还需要进一步的研究来证实其对胰岛素敏感性和代谢健康的长期影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Metabolism open Agricultural and Biological Sciences (General), Endocrinology, Endocrinology, Diabetes and Metabolism

自引率

0.00%

发文量

审稿时长

40 days